Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Breast Cancer Management Grows With Innovative, Better Tailored Treatment
March 13th 2022The historical boundaries of what was possible in the management of patients with breast cancer continue to be challenged, evidenced by the use of HER2-directed therapies in patients with brain metastases, de-escalated approaches in patients with visceral disease, and less-invasive surgical techniques for patients with lymph node involvement.
Read More
Biomarkers of Response Steer Treatment Selection in Breast Cancer
March 11th 2022Tiffany Traina, MD, discusses the body of evidence supporting the use of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, shifting standards of care in HER2-positive disease, as well as biomarkers of response with checkpoint inhibitors and PARP inhibitors in triple-negative breast cancer.
Read More
Precision Genomics Moves Toward Increased Granularity in Molecular Sequencing
March 10th 2022Kelvin P. Lee, MD, discusses the nuances of an effective molecular tumor board, explains the practical application of precision oncology genomics, and highlights the pathways that have the potential to change the treatment landscape for precision oncology.
Read More
Increasing Treatment Pathways Pave the Way for Heartening Future Throughout Hematologic Malignancies
March 9th 2022Stephen Oh, MD, PhD, discusses current and emerging agents in myelofibrosis, advances in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, updates in acute and chronic graft-vs-host-disease, and chronic lymphocytic leukemia management.
Read More
FDA Approval of Cilta-Cel Fast Tracks Multiple Myeloma Toward Curative Potential
March 7th 2022Sundar Jagannath, MBBS, discusses the significance of the FDA approval of ciltacabtagene autoleucel, important adverse effects to be aware of, and shared his thoughts on where the treatment fits into the current and future treatment paradigms.
Read More
NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update
March 3rd 2022The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b as a recommended treatment option for adult patients with polycythemia vera.
Read More
SABCS Generates Discussion Around SERDs, CDK4/6 Inhibitors, and ADCs in Breast Cancer
March 1st 2022From early phase 1/2 to pivotal phase 3 data, the 2021 San Antonio Breast Cancer Symposium was full of exciting research with selective estrogen receptor degraders, CDK4/6 inhibitors, and antibody-drug conjugates.
Read More
NCCN Guidelines List Ripretinib as Preferred Fourth-Line Option in Gastrointestinal Stromal Tumor
February 25th 2022Version 1.2022 of the National Comprehensive Cancer Network guidelines now include ripretinib as a category 1 fourth-line treatment option for patients with advanced gastrointestinal stromal tumor and as an additional TKI for consideration prior to surgery.
Read More
Real-World Study Shows Fast Uptake of Immunotherapy-Based Combinations in Frontline RCC
February 25th 2022The FDA approvals of immunotherapy-based combinations as frontline therapy led to a substantial increase in their use in patients with metastatic renal cell carcinoma in the community setting, leading to a greater use of TKI monotherapy as second- and third-line therapies.
Read More
Frontline Checkpoint Inhibition Shows Potential in mRCC With Poor Performance Status
February 22nd 2022The combinations of nivolumab plus ipilimumab and pembrolizumab plus axitinib demonstrated comparable activity and safety as frontline treatment in patients with metastatic renal cell carcinoma and a performance status of 2 or greater, according to findings from a retrospective study.
Read More
Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC
February 17th 2022The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Read More
Earlier Introduction of ADCs, PARP and CDK4/6 Inhibitors Improve Outcomes in Breast Cancer
February 13th 2022Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.
Read More
Prior Rituximab Reduces the Effectiveness of COVID-19 Vaccination in Lymphoma
February 9th 2022Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.
Read More
NCCN Voices a Call to Action Against Health Care Inequity on World Cancer Day
February 8th 2022The National Comprehensive Cancer Network is one of many organizations that is taking a stand against inequity in health care by aligning themselves with the new 3-year campaign, entitled “Close the Care Gap,” led by the Union for International Cancer Control.
Read More
Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC
February 7th 2022Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.
Read More
2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant
January 27th 2022The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.
Read More